Genomics

Company to deploy MPSS for the characterization of genomic changes in cancer

Published in Cancer Weekly, June 8th, 2004

Lynx Therapeutics, Inc., (LYNX) has recently entered into an agreement with the National Cancer Institute (NCI) to deploy Massively Parallel Signature Sequencing, or MPSS, for the characterization of genomic changes in cancer.

Under contract with the NCI, Lynx is applying MPSS to identify chromosome reconfigurations in human cancer. Every cancer has distinctive chromosomal rearrangements that are not present in the normal cells from which it arose. Lynx's patented "di-signature" technology enables the simultaneous characterization of millions of paired DNA fragments, separated by a defined genomic distance, from across the genome.

The fragment pairs...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-06-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry